Clinical Trial Update: 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy [Phase 4]

View source ↗

Summary

This Phase IV multicenter randomized open-label study compared saxagliptin to acarbose as add-on to metformin in patients with Type 2 Diabetes inadequately cont…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)
• Precose (acarbose)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2017-04-14